**Abstract**

*Salmonella Kentucky* ST198 (*S. Kentucky* ST198) is the most ubiquitous multidrug resistant (MDR) strain posing the greatest threat to public health, livestock and food industry in Africa. The reinvention of bacteriophage (Phage) as a non-antibiotic alternative only gives a glimmer of hope in the control of MDR strains of *Salmonellae*. *S. Kentucky* ST198 posses' chromosomal and plasmid factors capable of been co-opted into phage mediated transduction and co-transduction of antibiotic resistance genes (ARGs) as well as cross-serovar transduction of ARGs. Phage DT104, DT120 and P-22 like prophages like PDT17 and ES18 together have been shown to be capable of transducing and co-transducing the classical ACSSuT resistance phenotype identified in most *S. Kentucky* ST198 strain on the continent. Also, the institution of fluoroquinolones and third generation cephalosporin for salmonellosis treatment in animals or human infected by *S. Kentucky* ST198 strain resistant to these drugs can induce *Salmonella* phage transduction of kanamycin between different *Salmonella* serovars if present. This review highlights possible risk associated with the use of known *Salmonella* phages in the control of *S. Kentucky* ST198 and the need for chromosomal and plasmid tracking of genes prior to the institution of phage therapy on the continent.

**Keywords:** Bacteriophages, *Salmonella Kentucky* ST198, DT104, transduction, ARGs, *Salmonella* conjugative plasmids, Africa
